Alirocumab—a novel drug for familial hypercholesterolemia

Priyanka Kamath, Preethi J. Shenoy

Research output: Contribution to journalArticle

Abstract

Familial hypercholesterolemia (FH) is a genetically transmitted condition, wherein abnormally high levels of total cholesterol and low density lipoproteins (LDL) are seen. Occurrence of premature cardiovascular complications is common, resulting in significant morbidities and fatalities. Currently statins are the first-choice drugs to treat FH, given alone, or in combination with other lipid lowering drugs. Alirocumab is a monoclonal antibody directed against PCSK9, a ‘gain-of-function’ mutation of which is thought to be responsible for the defective processing of LDL cholesterol, resulting in lesser uptake of LDL-C into the hepatocytes. It was approved by the US-FDA in July 2015 as a first-in-class drug, “for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.” It has to be administered subcutaneously every 2 weeks, and the dose is titrated as per need. Injection-site reactions, myalgia, neurocognitive events, pruritus were the major adverse effects observed during clinical trials. Inhibition of PCSK 9 is a new promising target for the treatment of patients with familial hypercholesterolemia.

Original languageEnglish
Pages (from-to)345-348
Number of pages4
JournalNational Journal of Physiology, Pharmacy and Pharmacology
Volume6
Issue number4
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Hyperlipoproteinemia Type II
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Lipoproteins
Pharmaceutical Preparations
LDL Cholesterol
Myalgia
Pruritus
Hypercholesterolemia
Hepatocytes
Cardiovascular Diseases
Stroke
Myocardial Infarction
Monoclonal Antibodies
Clinical Trials
Diet
Morbidity
Lipids
Mutation
Injections
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{731b97b097324824a43cc2ed04883d3f,
title = "Alirocumab—a novel drug for familial hypercholesterolemia",
abstract = "Familial hypercholesterolemia (FH) is a genetically transmitted condition, wherein abnormally high levels of total cholesterol and low density lipoproteins (LDL) are seen. Occurrence of premature cardiovascular complications is common, resulting in significant morbidities and fatalities. Currently statins are the first-choice drugs to treat FH, given alone, or in combination with other lipid lowering drugs. Alirocumab is a monoclonal antibody directed against PCSK9, a ‘gain-of-function’ mutation of which is thought to be responsible for the defective processing of LDL cholesterol, resulting in lesser uptake of LDL-C into the hepatocytes. It was approved by the US-FDA in July 2015 as a first-in-class drug, “for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.” It has to be administered subcutaneously every 2 weeks, and the dose is titrated as per need. Injection-site reactions, myalgia, neurocognitive events, pruritus were the major adverse effects observed during clinical trials. Inhibition of PCSK 9 is a new promising target for the treatment of patients with familial hypercholesterolemia.",
author = "Priyanka Kamath and Shenoy, {Preethi J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.5455/njppp.2016.6.02032016135",
language = "English",
volume = "6",
pages = "345--348",
journal = "National Journal of Physiology, Pharmacy and Pharmacology",
issn = "2320-4672",
publisher = "Mrs Dipika Charan for MedScience Publishers",
number = "4",

}

Alirocumab—a novel drug for familial hypercholesterolemia. / Kamath, Priyanka; Shenoy, Preethi J.

In: National Journal of Physiology, Pharmacy and Pharmacology, Vol. 6, No. 4, 01.01.2016, p. 345-348.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alirocumab—a novel drug for familial hypercholesterolemia

AU - Kamath, Priyanka

AU - Shenoy, Preethi J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Familial hypercholesterolemia (FH) is a genetically transmitted condition, wherein abnormally high levels of total cholesterol and low density lipoproteins (LDL) are seen. Occurrence of premature cardiovascular complications is common, resulting in significant morbidities and fatalities. Currently statins are the first-choice drugs to treat FH, given alone, or in combination with other lipid lowering drugs. Alirocumab is a monoclonal antibody directed against PCSK9, a ‘gain-of-function’ mutation of which is thought to be responsible for the defective processing of LDL cholesterol, resulting in lesser uptake of LDL-C into the hepatocytes. It was approved by the US-FDA in July 2015 as a first-in-class drug, “for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.” It has to be administered subcutaneously every 2 weeks, and the dose is titrated as per need. Injection-site reactions, myalgia, neurocognitive events, pruritus were the major adverse effects observed during clinical trials. Inhibition of PCSK 9 is a new promising target for the treatment of patients with familial hypercholesterolemia.

AB - Familial hypercholesterolemia (FH) is a genetically transmitted condition, wherein abnormally high levels of total cholesterol and low density lipoproteins (LDL) are seen. Occurrence of premature cardiovascular complications is common, resulting in significant morbidities and fatalities. Currently statins are the first-choice drugs to treat FH, given alone, or in combination with other lipid lowering drugs. Alirocumab is a monoclonal antibody directed against PCSK9, a ‘gain-of-function’ mutation of which is thought to be responsible for the defective processing of LDL cholesterol, resulting in lesser uptake of LDL-C into the hepatocytes. It was approved by the US-FDA in July 2015 as a first-in-class drug, “for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.” It has to be administered subcutaneously every 2 weeks, and the dose is titrated as per need. Injection-site reactions, myalgia, neurocognitive events, pruritus were the major adverse effects observed during clinical trials. Inhibition of PCSK 9 is a new promising target for the treatment of patients with familial hypercholesterolemia.

UR - http://www.scopus.com/inward/record.url?scp=85006215425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006215425&partnerID=8YFLogxK

U2 - 10.5455/njppp.2016.6.02032016135

DO - 10.5455/njppp.2016.6.02032016135

M3 - Article

AN - SCOPUS:85006215425

VL - 6

SP - 345

EP - 348

JO - National Journal of Physiology, Pharmacy and Pharmacology

JF - National Journal of Physiology, Pharmacy and Pharmacology

SN - 2320-4672

IS - 4

ER -